Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials

International Journal of Antimicrobial Agents

Volumn 29, Issue 2, 2007, Pages 136-143

  Falagas, Matthew E ^a,b   Ntziora, Fotinie ^a   Betsi, Gregoria I ^a   Samonis, George ^c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Amphotericin; Antifungal treatment; Caspofungin; Fluconazole; Novel antifungal agents; Randomized controlled trials (RCTs)

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; DEOXYCHOLIC ACID; FLUCONAZOLE;

ANTIFUNGAL ACTIVITY; CANDIDIASIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA EXTRACTION; DRUG EFFICACY; DRUG FEVER; DRUG WITHDRAWAL; HUMAN; HYPOKALEMIA; MEDICAL LITERATURE; META ANALYSIS; MORTALITY; MYCOSIS; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK; RISK ASSESSMENT; SHORT SURVEY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; HUMANS; MYCOSES; PEPTIDES, CYCLIC; RANDOMIZED CONTROLLED TRIALS;

EID: 33846062480     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.09.018     Document Type: Short Survey

References (79)

1. Sims C.R., Ostrosky-Zeichner L., and Rex J.H. Invasive candidiasis in immunocompromised hospitalized patients. Arch Med Res 36 (2005) 660-671
2. Pavie J., Lacroix C., Hermoso D.G., et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol 43 (2005) 4902-4904
3. De Miguel D., Gomez P., Gonzalez R., et al. Nonfatal pulmonary Trichoderma viride infection in an adult patient with acute myeloid leukemia: report of one case and review of the literature. Diagn Microbiol Infect Dis 53 (2005) 33-37
4. Maschmeyer G., Haas A., and Bohme A. Update on therapy of invasive mycoses in hematology and oncology. Dtsch Med Wochenschr 130 (2005) 1381-1384 [in German]
5. Forestier E., Remy V., Lesens O., et al. A case of Aspergillus mediastinitis after heart transplantation successfully treated with liposomal amphotericin B, caspofungin and voriconazole. Eur J Clin Microbiol Infect Dis 24 (2005) 347-349
6. Ludwig M., Schneider H., Lohmeyer J., et al. Systemic aspergillosis with predominant genitourinary manifestations in an immunocompetent man: what we can learn from a disastrous follow-up. Infection 33 (2005) 90-92
7. Golan Y. Overview of transplant mycology. Am J Health Syst Pharm 62 Suppl. 1 (2005) S17-S21
8. Perfect J.R. Management of invasive mycoses in hematology patients: current approaches. Oncology (Williston Park) 18 (2004) 5-14
9. Hamza N.S., Ghannoum M.A., and Lazarus H.M. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 34 (2004) 377-389
10. Steinbach W.J., Schell W.A., Miller J.L., Perfect J.R., and Martin P.L. Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients. J Infect 48 (2004) 112-116
11. Perea S., and Patterson T.F. Invasive Aspergillus infections in hematologic malignancy patients. Semin Respir Infect 17 (2002) 99-105
12. Ruhnke M., and Maschmeyer G. Management of mycoses in patients with hematologic disease and cancer, review of the literature. Eur J Med Res 7 (2002) 227-235
13. Maschmeyer G. New antifungal agents-treatment standards are beginning to grow old. J Antimicrob Chemother 49 (2002) 239-241
14. Betts R., Glasmacher A., Maertens J., et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 106 (2006) 466-473
15. Steinbach W.J. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Curr Drug Targets Infect Disord 5 (2005) 203-210
16. McCormack P.L., and Perry C.M. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 65 (2005) 2049-2068
17. Vazquez J.A. Anidulafungin: a new echinocandin with a novel profile. Clin Ther 27 (2005) 657-673
18. Maschmeyer G., and Glasmacher A. Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin. Mycoses 48 (2005) 227-234
19. Krcmery Jr. V.C. Antifungal chemotherapeutics. Med Princ Pract 14 (2005) 125-135
20. Perfect J.R. Antifungal resistance: the clinical front. Oncology (Williston Park) 18 (2004) 15-22
21. Marr K. Combination antifungal therapy: where are we now, and where are we going?. Oncology (Williston Park) 18 (2004) 24-29
22. Perfect J.R. Use of newer antifungal therapies in clinical practice: what do the data tell us?. Oncology (Williston Park) 18 (2004) 15-23
23. Magiorakos A.P., and Hadley S. Impact of real-time fungal susceptibility on clinical practices. Curr Opin Infect Dis 17 (2004) 511-515
24. Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 23 (2004) 805-812
25. Gallagher J.C., MacDougall C., Ashley E.S., and Perfect J.R. Recent advances in antifungal pharmacotherapy for invasive fungal infections. Expert Rev Anti Infect Ther 2 (2004) 253-268
26. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 20 (2003) 121-136
27. Boucher H.W., Groll A.H., Chiou C.C., and Walsh T.J. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 64 (2004) 1997-2020
28. Ruhnke M. Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment. Drugs 64 (2004) 1163-1180
29. Rubin Z.A., and Somani J. New options for the treatment of invasive fungal infections. Semin Oncol 31 (2004) 91-98
30. Abuhammour W., and Habte-Gaber E. Newer antifungal agents. Indian J Pediatr 71 (2004) 253-259
31. Schwartz S., and Thiel E. CNS-aspergillosis: are there new treatment options?. Mycoses 46 (2003) 8-14
32. Burnie J., and Matthews R. Genetically recombinant antibodies: new therapeutics against candidiasis. Expert Opin Biol Ther 4 (2004) 233-241
33. Wingard J.R., and Leather H. A new era of antifungal therapy. Biol Blood Marrow Transplant 10 (2004) 73-90
34. Wong-Beringer A., and Kriengkauykiat J. Systemic antifungal therapy: new options, new challenges. Pharmacotherapy 23 (2003) 1441-1462
35. Denning D.W. Echinocandin antifungal drugs. Lancet 362 (2003) 1142-1151
36. Keating G., and Figgitt D. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs 63 (2003) 2235-2263
37. Kartsonis N.A., Nielsen J., and Douglas C.M. Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat 6 (2003) 197-218
38. Wiederhold N.P., and Lewis R.E. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 12 (2003) 1313-1333
39. Girmenia C., and Martino P. New antifungal drugs and new clinical trials: interpreting results may be difficult. Curr Opin Oncol 15 (2003) 283-288
40. Ullmann A.J. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin 19 (2003) 263-271
41. Sutton D.A. Laboratory evaluation of new antifungal agents against rare and refractory mycoses. Curr Opin Infect Dis 15 (2002) 575-582
42. Johnson M.D., and Perfect J.R. Caspofungin: first approved agent in a new class of antifungals. Expert Opin Pharmacother 4 (2003) 807-823
43. Vazquez J.A. Invasive oesophageal candidiasis: current and developing treatment options. Drugs 63 (2003) 971-989
44. Cornely O.A., Schmitz K., and Aisenbrey S. The first echinocandin: caspofungin. Mycoses 45 (2002) 56-60
45. Letscher-Bru V., and Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 51 (2003) 513-521
46. Polak A. Antifungal therapy-state of the art at the beginning of the 21st century. Prog Drug Res 2003;Spec No:59-190.
47. Chandrasekar P.H., and Manavathu E.K. Caspofungin. Drugs Today (Barc) 38 (2002) 829-846
48. Pacetti S.A., and Gelone S.P. Caspofungin acetate for treatment of invasive fungal infections. Ann Pharmacother 37 (2003) 90-98
49. Sable C.A., Nguyen B.Y., Chodakewitz J.A., and DiNubile M.J. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 4 (2002) 25-30
50. Arathoon E.G. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 14 (2001) 685-691
51. Stone E.A., Fung H.B., and Kirschenbaum H.L. Caspofungin: an echinocandin antifungal agent. Clin Ther 24 (2002) 351-377
52. Groll A.H., and Walsh T.J. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 10 (2001) 1545-1558
53. Graybill J.R. Hitting a new target with echinocandins. Why chase something else?. Curr Opin Investig Drugs 2 (2001) 468-471
54. Hoang A. Caspofungin acetate: an antifungal agent. Am J Health Syst Pharm 58 (2001) 1206-1214
55. Georgopapadakou N.H. Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert Opin Investig Drugs 10 (2001) 269-280
56. DiNubile M.J., Hille D., Sable C.A., and Kartsonis N.A. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. J Infect 50 (2005) 443-449
57. Stone J.A., Migoya E.M., Hickey L., et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 48 (2004) 4306-4314
58. Walsh T.J., Teppler H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 (2004) 1391-1402
59. Colombo A.L., Perfect J., DiNubile M., et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22 (2003) 470-474
60. Arathoon E.G., Gotuzzo E., Noriega L.M., Berman R.S., DiNubile M.J., and Sable C.A. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 46 (2002) 451-457
61. Mora-Duarte J., Betts R., Rotstein C., et al. Caspofungin invasive candidiasis study group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
62. Villanueva A., Gotuzzo E., Arathoon E.G., et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 113 (2002) 294-299
63. Dinubile M.J., Lupinacci R.J., Berman R.S., and Sable C.A. Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin. AIDS Res Hum Retroviruses 18 (2002) 903-908
64. Stone J.A., Holland S.D., Wickersham P.J., et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 46 (2002) 739-745
65. Villanueva A., Arathoon E.G., Gotuzzo E., Berman R.S., DiNubile M.J., and Sable C.A. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33 (2001) 1529-1535
66. Jadad A., Moore A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996) 1-12
67. Betts R., Glasmacher A., Maertens J., et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 106 (2006) 466-473
68. Abruzzo G.K., Gill C.J., Flattery A.M., et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 44 (2000) 2310-2318
69. Abruzzo G.K., Flattery A.M., Gill C.J., et al. Evaluation of the echinocandin antifungal MK-0991 (L-743, 872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 41 (1997) 2333-2338
70. MacCallum D.M., and Odds F.C. Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection. Antimicrob Agents Chemother 48 (2004) 4911-4914
71. Ramage G., VandeWalle K., Bachmann S.P., Wickes B.L., and Lopez-Ribot J.L. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 46 (2002) 3634-3636
72. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47 (2003) 3149-3154
73. Zaoutis T.E., Foraker E., McGowan K.L., et al. Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals. Diagn Microbiol Infect Dis 52 (2005) 295-298
74. Cuerca-Estella M., Rodriguez D., Almirante B., et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 55 (2005) 194-199
75. Arikan S., Sancak B., and Hascelik G. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital. Med Mycol 43 (2005) 171-178
76. Ju J.Y., Polhamus C., Marr K.A., Holland S.M., and Bennett J.E. Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice. Antimicrob Agents Chemother 46 (2002) 1240-1245
77. Barchiesi F., Spreghini E., Tomassetti S., Arzeni D., Giannini D., and Scalise G. Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. Antimicrob Agents Chemother 49 (2005) 4989-4992
78. Wegner B., Baer P., Gauer S., Oremek G., Hauser L.A., and Geiger H. Caspofungin is less nephrotoxic than amphotericin B in vitro and predominantly damages distal renal tubular cells. Nephrol Dial Transplant 20 (2005) 2071-2079
79. Keating G., and Figgitt D. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs 63 (2003) 2235-2263